The magnitude of the beat and guidance raise is significant for a $202M market cap stock. The removal of Hyalofast from 2027 guidance introduces a binary catalyst risk (FDA PMA decision) that could drive the next leg. Traders should monitor the Q3 earnings call for updates on Hyalofast PMA discussions and Cingal NDA timeline, as positive regulatory news would remove the primary overhang on the 2027 outlook.
Price Chart
Executive Summary
Anika Therapeutics reported a transformative Q2 2026 beat, with GAAP EPS of $0.24 (vs $0.03 consensus) and revenue of $32.6M (vs $29.2M consensus), driven by record Commercial Channel revenue of $13.9M (+17% YoY) and gross margin expansion to 65%. The company raised full-year 2026 guidance across all metrics, most notably lifting adjusted EBITDA margin guidance from 5%-10% to 13%-17%, signaling a structural profitability inflection. The bullish read is tempered by the removal of Hyalofast revenue from 2027 guidance due to FDA timing uncertainty, but the magnitude of the beat and guidance raise dominates the narrative for a $202M market cap stock.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $32.6M, up 16% YoY vs $28.2M, beating $29.2M consensus
- GAAP diluted EPS $0.24 vs consensus $0.03 (700% beat); adjusted diluted EPS $0.42
- Gross margin expanded to 65% from 51% in Q2 2025, driven by volume and mix
- Adjusted EBITDA $7.1M (22% margin), highest since 2020, vs -$0.2M in Q2 2025
- Raised FY2026 guidance: total revenue growth 5%-10% (prev. 1%-9%), adj. EBITDA margin 13%-17% (prev. 5%-10%)
- Commercial Channel revenue hit record $13.9M, +17% YoY; International revenue record $12.6M, +22% YoY
- Removed Hyalofast revenue from 2027 guidance due to FDA timing uncertainty; new policy: forecast only approved products
- Cash and equivalents $38.4M as of June 30, 2026, down from $57.5M at Dec 2025 due to share repurchases and inventory build
Financial Impact
Q2 revenue beat consensus by $3.4M (11.6%); GAAP EPS beat by $0.21 (700%); FY2026 EBITDA margin guidance raised from 5-10% to 13-17%, implying ~$7-10M incremental EBITDA on ~$120M revenue
Risk Factors
- Hyalofast PMA uncertainty: FDA deficiency letter and removal from 2027 guidance creates binary outcome risk
- Cash burn: operating cash flow -$5.5M YTD and cash down $19M from Dec 2025 due to share repurchases and inventory build
- Second-half moderation expected: management guided for slower H2 vs H1 due to OEM order timing
- Small analyst coverage (1 analyst) limits institutional visibility and liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-004977 |
| Document: f8k_072926.htm | 0001171843-26-004977 |
| Document: 0001171843-26-004977-index-headers.html | 0001171843-26-004977 |
| Document: 0001171843-26-004977-index.html | 0001171843-26-004977 |
| Document: 0001171843-26-004977.txt | 0001171843-26-004977 |
| 8-K Data (Synthetic) | 0001171843-26-004977 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | 8-K | $16.17 $21.68 | ▲ +34.08% | ▲ +29.06% | $19.10 (+18.12%) |
Jul 14, 2026 11w ago | 8-K | $15.93 $22.03 | ▲ +38.29% | ▲ +35.95% | $19.10 (+19.90%) |
Jun 23, 2026 14w ago | 8-K | $14.73 $15.01 | ▲ +1.90% | ▼ −0.03% | $19.10 (+29.67%) |
Jun 11, 2026 16w ago | Institutional Cluster | $14.72 $15.60 | ▼ −5.98% | ▼ −4.20% | $19.10 (−29.76%) |
Jun 8, 2026 16w ago | DEFA14A | $14.60 $16.03 | ▲ +9.79% | ▲ +8.16% | $19.10 (+30.82%) |
Jun 1, 2026 17w ago | DEFA14A | $14.63 $14.63 | · 0.00% | ▲ +1.30% | $19.10 (+30.55%) |
Apr 30, 2026 22w ago | Insider Cluster | $12.45 $14.90 | ▲ +19.68% | ▲ +14.71% | $19.10 (+53.41%) |
Apr 29, 2026 22w ago | 8-K | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 28, 2026 22w ago | DEFA14A | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 15, 2026 24w ago | Press Release | $15.39 $14.80 | ▼ −3.83% | ▼ −9.65% | $19.10 (+24.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access